Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia

Schizophrenia Research

Volumn 77, Issue 2-3, 2005, Pages 167-177

  Ren, Xinhua S ^a,b   Kazis, Lewis E ^a,b   Lee, Austin F ^a,b,c   Huang, Yu Hui ^a,b   Hamed, Alaa ^a   Cunningham, Francesca ^d,e   Herz, Lawrence ^b,f   Miller, Donald R ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Boston University   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotics; Initiation pattern; Patient characteristics; Schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; RISK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COMORBIDITY; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 23444452245     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.04.005     Document Type: Article

References (37)

1. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, M.C. Infante, and P.J. Weiden Anti-psychotic-induced weight gain: a comprehensive research synthesis Am. J. Psychiatry 156 1999 1686 1696
2. N. Andreason Symptoms, signs, and diagnosis of schizophrenia Lancet 346 1995 477 481
3. N. Andreason, A. Stephan, A. Randall, D. Miller, and M. Flaum Symptoms of schizophrenia: methods, meanings, and mechanisms Arch. Gen. Psychiatry 52 1995 341 351
4. M. Atkinson, S. Zibin, and H. Chuang Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology Am. J. Psychiatry 154 1997 99 105
5. M. Chakos, J. Lieberman, E. Hoffman, D. Bradford, and B. Sheitman Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials Am. J. Psychiatry 158 2001 518 526
6. J.A. Chiles, A.L. Miller, M.L. Crismon, A.J. Rush, A.S. Krasnoff, and S.S. Shon The Texas medication algorithm project: development and implementation of the schizophrenia algorithm Psychiatr. Serv. 50 1999 69 74
7. L. Citrome, and J. Volavska Optimal dosing of atypical anti-psychotics in adults: a review of the current evidence Harv. Rev. Psychiatr. 10 2002 280 291
8. B. Dickey, H. Wagenaar, and A. Stewart Using health status measures with the seriously mentally ill in health services research Med. Care 34 1996 112 116
9. L. Dixon, L. Postrado, J. Delahanty, P. Fisher, and A. Lehman The association of medical comorbidity in schizophrenia with poor physical and mental health J. Nerv. Ment. Dis. 187 1999 496 502
10. L. Dixon, R. Goldberg, A. Lehman, and S. McNary The impact of health status on work, symptoms, and functional outcomes in severe mental illness J. Nerv. Ment. Dis. 189 2001 17 23
11. B. Felker, J.J. Yazel, and D. Short Mortality and medical comorbidity among psychiatry patients: a review Psychiatr. Serv. 47 1996 1356 1363
12. E.J. Frackiewicz, J.J. Sramek, K. Herrera, N.M. Kurtz, and N.R. Cutler Ethnicity and antipsychotic response Ann. Pharmacother. 31 1997 1360 1369
13. M.A. Fuller, K.M. Shermock, M. Secic, J.S. Laich, and M.B. Durkin Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine Psychiatr. Serv. 53 2002 855 860
14. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153 1996 321 330
15. Haaro, J.M., Edgell, E., Jones, P., Naber, D., Mavreas, V. and Slooff, C., 2003. Change in clinical status and functioning over the first six months of treatment: results from the schizophrenia outpatient health outcomes (SOHO) study. Abstract, presented at the annual meeting of the American Psychiatric Association, San Francisco, CA.
16. C. Harding, J.S. Strauss, and J. Zubin Chronicity in schizophrenia: revisited Br. J. Psychiatry 161 1992 27 37
17. P.D. Harvey, J. Lombardi, M. Leiman, L. White, M. Parella, P. Powchik, and M. Davidson Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study Schizophr. Res. 22 1996 223 231
18. R.C. Hermann, D.M. Yang, S.L. Ettner, S.C. Marcus, C. Yoon, and M. Abraham Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997 Psychiatr. Serv. 53 2002 425 430
19. D.V. Jeste, M. Klausner, M. Brecher, C. Clyde, and R. Jones A clinical evaluation of risperidone in the treatment of schizophrenia: a 10 week, open-label, multicenter trial (ARCS study group: assessment of risperdal in a clinical setting) Psychopharmacology 131 1997 239 247
20. J.M. Kane Drug therapy: schizophrenia N. Engl. J. Med. 334 1996 34 41
21. L.E. Kazis, D. Miller, J. Clark, S. Katherine, A.F. Lee, W. Rogers, A. Spiro, S. Payne, G. Fincke, A. Selim, and M. Linzer Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study Arch. Intern. Med. 158 1998 626 632
22. L.E. Kazis, X.S. Ren, A.F. Lee, S. Katherine, W. Rogers, J. Clark, and D.R. Miller Health status in VA patients: results from the Veterans Health Study using the Veterans SF-36 Am. J. Med. Qual. 14 1999 28 38
23. J. Lamoreaux The organizational structure for medical information management in the Department of Veterans Affairs: an overview of major health care databases Med. Care 34 1996 MS31 MS44
24. D.L. Leslie, and R.A. Rosenheck Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors Med. Care 39 2001 923 933
25. S. Leucht, G. Pitschel-Walz, D. Abraham, and W. Kissling Efficacy and extrapyramidal effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials Schizophr. Res. 35 1999 51 68
26. G.G. Liu, S.X. Sun, D.B. Christensen, and X. Luo Cost comparisons of olanzapine and risperidone in treating schizophrenia Ann. Pharmacother. 38 2004 134 141
27. K.G. MacDonald Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity Arch. Surg. 2003 357 360
28. C.J.L. Murray A.D. Lopez Summary: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 1996 Harvard University Press Cambridge, MA
29. C.B. Nemeroff Dosing the antipsychotic medication olanzapine J. Clin. Psychiatry 58 1997 45 49
30. D.A. Regier, W.E. Narrow, D.S. Rae, R.W. Manderscheid, B.Z. Locke, and F.K. Goodwin The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services Arch. Gen. Psychiatry 50 1993 85 94
31. X.S Ren, L. Kazis, A.F. Lee, A. Hamed, Y.H. Huang, F. Cunningham, and D.R. Miller Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia J. Clin. Pharm. Ther. 27 2003 441 451
32. X.S. Ren, A.F. Lee, Y.H. Huang, A. Hamed, L. Herz, D.R. Miller, and L. Kazis Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia J. Clin. Pharm. Ther. 29 2004 471 481
33. X.S. Ren, Y.H. Huang, A.F. Lee, D.R. Miller, S. Qian, and L. Kazis Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia J. Clin. Pharm. Ther. 30 2005 65 71
34. R. Rosenheck, L. Douglas, and S. Michael From clinical real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs Med. Care 39 2002 302 308
35. M.A. Roy, and X. De Vriendt Positive and negative symptoms in schizophrenia. A current overview Can. J. Psychiatry 39 1994 407 414
36. D. Whitehorn, Q. Rui, and L.C. Kopala Outcomes benchmarks: changes in symptom and function outcome measures from year one to year two endpoints with continuous treatment for a schizophrenia spectrum disorder Schizophr. Res. 60 2003 348
37. B. Zhu, P.J. Gibson, H. Ascher-Svanum, and J. Opolka A comparison of adherence and persistence levels among schizophrenia patients treated with atypical antipsychotics Schizophr. Res. 60 2003 349